Added to YB: 2025-12-02
Pitch date: 2025-11-28
NOVO-B.CO [neutral]
Novo Nordisk A/S
+1.92%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 315.10
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 28/11/2025 - NOVOB – Go Evoke, go broke
NOVO-B.CO (update): Evoke Alzheimer's drug failed Phase III trials, missing statistically significant reduction in disease progression. Heavy selloff despite weak prior sentiment. Trades at discounted 13.6x 2026 consensus earnings, 3.7% yield reflects lowered expectations.
Read full article (1 min)